These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

628 related items for PubMed ID: 15256471

  • 1. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ.
    Cancer Res; 2004 Jul 15; 64(14):4973-9. PubMed ID: 15256471
    [Abstract] [Full Text] [Related]

  • 2. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
    Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL.
    Cancer Res; 2001 Feb 01; 61(3):842-7. PubMed ID: 11221866
    [Abstract] [Full Text] [Related]

  • 3. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
    Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW.
    Clin Cancer Res; 2005 Jul 15; 11(14):5292-9. PubMed ID: 16033848
    [Abstract] [Full Text] [Related]

  • 4. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, Chen W, Ohlfest JR.
    J Immunother; 2007 Jul 15; 30(8):789-97. PubMed ID: 18049330
    [Abstract] [Full Text] [Related]

  • 5. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ.
    Gynecol Oncol; 2006 Mar 15; 100(3):469-78. PubMed ID: 16249018
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
    Katano M, Morisaki T, Koga K, Nakamura M, Onishi H, Matsumoto K, Tasaki A, Nakashima H, Akiyoshi T, Nakamura M.
    Anticancer Res; 2005 Mar 15; 25(6A):3771-6. PubMed ID: 16302738
    [Abstract] [Full Text] [Related]

  • 7. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon MJ, Parham GP.
    Am J Obstet Gynecol; 2000 Sep 15; 183(3):601-9. PubMed ID: 10992180
    [Abstract] [Full Text] [Related]

  • 8. [An in vitro study of specific antitumor immunity induced by dendritic cells pulsed with tumor cell lysates from patients with hepatocellular carcinoma].
    Gao J, Chen M, Peng ML, Ren H.
    Zhonghua Gan Zang Bing Za Zhi; 2005 Mar 15; 13(3):198-201. PubMed ID: 15760555
    [Abstract] [Full Text] [Related]

  • 9. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, Leccia MT, Lesimple T, Wijdenes J, Bartholeyns J, Fridman WH, Salcedo M, Ferries E, Tartour E.
    J Immunother; 2008 Jan 15; 31(1):101-12. PubMed ID: 18157017
    [Abstract] [Full Text] [Related]

  • 10. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T, Kamigaki T, Nakamura T, Imanishi T, Hayashi S, Kawasaki K, Takase S, Ajiki T, Kuroda Y.
    Oncol Rep; 2006 Dec 15; 16(6):1317-24. PubMed ID: 17089056
    [Abstract] [Full Text] [Related]

  • 11. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID, Chen Q, Morris L, Quirk J, Stanley M, Tavarnesi ML, Parente P, Cavicchiolo T, Hopkins W, Jackson H, Dimopoulos N, Tai TY, MacGregor D, Browning J, Svobodova S, Caron D, Maraskovsky E, Old LJ, Chen W, Cebon J.
    J Immunother; 2006 Dec 15; 29(5):499-511. PubMed ID: 16971806
    [Abstract] [Full Text] [Related]

  • 12. Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma.
    Onishi H, Morisaki T, Baba E, Nakamura M, Inaba S, Kuroki H, Matsumoto K, Katano M.
    Anticancer Res; 2011 Nov 15; 31(11):3995-4005. PubMed ID: 22110233
    [Abstract] [Full Text] [Related]

  • 13. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.
    Yang W, Feng J, Chang X, Fu T, Ye X, Zhang H, Li X, Wen H, Feng L, Tong C, Cui H.
    Gynecol Oncol; 2007 Apr 15; 105(1):238-43. PubMed ID: 17383546
    [Abstract] [Full Text] [Related]

  • 14. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K, Shimodaira S, Maejima S, Udagawa N, Sano K, Higuchi Y, Koya T, Ochiai T, Koide M, Uehara S, Nakamura M, Sugiyama H, Yonemitsu Y, Okamoto M, Hongo K.
    J Neurosurg; 2015 Oct 15; 123(4):989-97. PubMed ID: 26252465
    [Abstract] [Full Text] [Related]

  • 15. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
    De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW.
    Clin Cancer Res; 2008 May 15; 14(10):3098-104. PubMed ID: 18483377
    [Abstract] [Full Text] [Related]

  • 16. Immunotherapy of intracranial G422 glioblastoma with dendritic cells pulsed with tumor extract or RNA.
    Zhang Z, Tang LL, Zhan RY, Tong Y, Yao HP, Du LA.
    J Zhejiang Univ Sci; 2004 Oct 15; 5(10):1298-303. PubMed ID: 15362204
    [Abstract] [Full Text] [Related]

  • 17. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
    Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD.
    Clin Cancer Res; 2005 Aug 01; 11(15):5515-25. PubMed ID: 16061868
    [Abstract] [Full Text] [Related]

  • 18. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis.
    Ackermann B, Tröger A, Glouchkova L, Körholz D, Göbel U, Dilloo D.
    Klin Padiatr; 2004 Aug 01; 216(3):176-82. PubMed ID: 15175963
    [Abstract] [Full Text] [Related]

  • 19. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
    Okada H, Tsugawa T, Sato H, Kuwashima N, Gambotto A, Okada K, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Chambers WH, Potter DM, Storkus WJ, Pollack IF.
    Cancer Res; 2004 Aug 15; 64(16):5830-8. PubMed ID: 15313927
    [Abstract] [Full Text] [Related]

  • 20. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.
    J Immunother; 2006 Aug 15; 29(5):545-57. PubMed ID: 16971810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.